Pacira BioSciences, Inc. (PCRX) · Oct 8, 2026 · Acquisition

Pacira acquisition: Viatris buys PCRX for $1.65B cash

$1.65B acquisition — $36.50/share cash; $1.65B equity value

Pacira’s acquisition by Viatris delivers $36.50 per share in cash, but ends its standalone 5x30 growth strategy and pipeline upside.

Pacira was pursuing a standalone 5x30 strategy built around growing EXPAREL and ZILRETTA, improving profitability, and advancing pipeline assets such as PCRX-201. Its recent investor messaging emphasized improving commercial momentum, patent visibility through 2030, share repurchases, and a longer-term pipeline rather than a sale.

The filing replaces that standalone plan with a certain cash exit. Viatris agreed to acquire Pacira for $36.50 per share in cash, valuing the equity at $1.65 billion (Transaction terms). For Pacira holders, the key change is certainty of cash consideration rather than continued exposure to the upside—or execution risk—of the 5x30 strategy and PCRX-201 pipeline.

Filing figureAmountFiling context
Cash offer price$36.50 per shareTransaction terms
Aggregate equity value$1.65 billionTransaction terms
Last-twelve-month revenueApproximately $746 millionCompany overview
Last-twelve-month adjusted EBITDAApproximately $177 millionCompany overview
Expected closingBy end of 2026Transaction terms

The strategic logic is real, but the filing does not establish a clean standalone-company benchmark. Pacira brings Viatris two established, high-margin, patent-protected products and roughly $177 million of trailing adjusted EBITDA, while Viatris contributes broader commercial reach, lifecycle-management expertise, and global infrastructure (Company overview). That supports the deal as a strategic monetization of Pacira’s commercial base, but the filing gives no pre-deal share price, premium, or competing bid against which to call the cash price a clear financial win.

For Pacira’s business, this is more transition than acceleration. Viatris says it intends to expand EXPAREL and ZILRETTA across selected markets and leverage its infrastructure, but Pacira’s independent capital allocation, development priorities, and 5x30 execution now become part of Viatris’ broader portfolio strategy. Pacira’s board unanimously recommends the tender, and the transaction requires majority tender participation plus regulatory clearance (Transaction terms). 〔0〕

The deal is announced, not closed. The tender offer has not yet commenced; Viatris still must file its offer materials, Pacira must file its recommendation statement, and the transaction is expected to close by the end of 2026 (Tender offer and closing conditions). 〔1〕

Bottom line: This is a major strategic event that crystallizes value for Pacira holders but ends the company’s independent 5x30 and pipeline story. The business moves from a standalone growth platform to an acquired specialty-pharma franchise, with completion and integration still ahead.

What to watch next

Tender offer launch and Schedule TO/14D-9 filings

Original filing on SEC EDGAR

More Pacira BioSciences, Inc. news

Pacira acquisition: Viatris buys PCRX for $1.65B cash | PCRX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.